Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cancer vaccine NY-ESO-1 - Therion Biologics

Drug Profile

Cancer vaccine NY-ESO-1 - Therion Biologics

Alternative Names: Recombinant vaccinia/fowlpox NY-ESO-1 cancer vaccine - Therion Biologics

Latest Information Update: 05 Jan 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Therion Biologics
  • Developer Ludwig Institute for Cancer Research; Therion Biologics
  • Class Cancer vaccines; Peptide vaccines; Peptides; Saponins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 23 Nov 2006 Clinical data have been added to the adverse events and Cancer pharmacodynamics as well as therapeutic trials sections
  • 04 Jul 2003 Data presented at the 39th Annual Meeting if the American Society of Clinical Oncology (ASCO-2003) have been added to the pharmacodynamics and Cancer therapeutic trials section
  • 19 Sep 2002 Therion Biologics has entered into a non-exclusive licensing agreement with Boehringer Ingelheim Pharmaceuticals for ICAM-1
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top